Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

barusiban

Known as: C4.6,S1-Cyclo(N-(3-sulfanylpropanoyl)-D-tryptophyl-L-isoleucyl-L-alloisoleucyl-L-asparaginyl-L-2-aminobutanoyl-N-methyl-L-ornithinol) 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Barusiban, a selective oxytocin receptor antagonist: placental transfer in rabbit, monkey, and human†
Abstract The use of drugs in pregnancy always raises concerns regarding potential fetal exposure and possible adverse effects… Expand
2014
2014
Late preterm birth is associated with short‐term morbidity but not with adverse neurodevelopmental and physical outcomes at 1 year
We compared the neonatal and infant outcomes at one year (Bayley mental and psychomotor development index, and physical growth… Expand
2013
2013
Barusiban injection and preparation method thereof
The invention relates to the technical field of medicine and discloses a barusiban injection and a preparation method thereof… Expand
2009
2009
The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial.
OBJECTIVE The objective of the study was to compare barusiban with placebo in threatened preterm labor. STUDY DESIGN This was a… Expand
2007
2007
Barusiban suppresses oxytocin-induced preterm labour in non-human primates
BackgroundPreterm labour (PTL) is a major cause of neonatal mortality and morbidity, and oxytocin (OT) antagonists are potential… Expand
  • table 1
2007
2007
Use of barusiban in a novel study design for evaluation of tocolytic agents in pregnant and neonatal monkeys, including behavioural and immunological endpoints.
The oxytocin receptor antagonist barusiban, currently being developed for treatment of preterm labour, was investigated in… Expand
2006
2006
Barusiban, An Effective Long-Term Treatment of Oxytocin-Induced Preterm Labor in Nonhuman Primates1
Abstract Preterm labor (PTL) affects up to 25% of human pregnancies in developing countries, but there are few therapeutic… Expand
2005
2005
Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor.
Preterm labor (PTL) represents a significant unmet clinical need that affects up to 20% of all pregnancies and is a leading cause… Expand
2005
2005
Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in… Expand
Highly Cited
2004
Highly Cited
2004
Inhibitory Effect of Barusiban and Atosiban on Oxytocin-Induced Contractions of Myometrium From Preterm and Term Pregnant Women
Background: A synthetic oxytocin analogue, barusiban, was shown to potently inhibit oxytocininduced activity of myometrium from… Expand
  • figure 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE